KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting.
Professor Merrick Ross, M.D., of the MD Anderson Cancer Center in Houston, Texas, and a Principal Investigator for the Phase 2 study of PV-10 for metastatic melanoma, will deliver a presentation entitled “Intralesional therapy: local/regional control and implications for systemic response,” at 3:15 p.m. EST. The congress will be held at the Marriott Waterside Hotel in Tampa, Florida from November 9 - 13.
The abstract can be accessed at the following link: http://onlinelibrary.wiley.com/doi/10.1111/j.1755-148X.2011.00909.x/pdf.
Further information on the congress can be found at the following link: http://www.melanoma2011.com/.
Dr. Craig Dees, PhD, CEO of Provectus said, “As we prepare for a multi-center, global Phase 3 trial for PV-10 for metastatic melanoma, we look forward to Dr. Ross’s presentation, and his discussion of the Phase 2 results, at this major international meeting.”
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
Forward Looking Statement- Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See Provectus Pharmaceuticals, Inc.’s filings with the United States Securities and Exchange Commission, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.